IL-13 signaling via IL-13Ralpha2 triggers TGF-beta1-dependent allograft fibrosis by Brunner, Stefan et al.
TRANSPLANTATION 
RESEARCH
Brunner et al. Transplantation Research 2013, 2:16
http://www.transplantationresearch.com/content/2/1/16RESEARCH Open AccessIL-13 signaling via IL-13Rα2 triggers
TGF-β1-dependent allograft fibrosis
Stefan M Brunner1*, Gabriela Schiechl1, Rebecca Kesselring1, Maria Martin1, Saidou Balam1, Hans J Schlitt1,
Edward K Geissler1 and Stefan Fichtner-Feigl1,2Abstract
Background: Allograft fibrosis still remains a critical problem in transplantation, including heart transplantation. The
IL-13/TGF-β1 interaction has previously been identified as a key pathway orchestrating fibrosis in different
inflammatory immune disorders. Here we investigate if this pathway is also responsible for allograft fibrosis and if
interference with the IL-13/TGF-β1 interaction prevents allograft fibrosis.
Methods: FVB or control DBA/1 donor hearts were transplanted heterotopically into DBA/1 recipient mice and
hearts were explanted at day 60 and 100 post-transplantation. Cardiac tissue was examined by Masson’s trichrome
staining and immunohistochemistry for CD4, CD8, CD11b, IL-13, Fas ligand, matrix metalloproteinase (MMP)-1,
MMP-13, β2-microglobulin, and Gremlin-1. Graft-infiltrating cells were isolated and analyzed by flow cytometry. IL-13
and TGF-β1 levels were determined by enzyme-linked immunosorbent assay (ELISA) and the amount of collagen
was quantified using a Sircol assay; IL-13Rα2 expression was detected by Western blotting. In some experiments
IL-13/ TGF-β1 signaling was blocked with specific IL-13Rα2 siRNA. Additionally, a PCR array of RNA isolated from the
allografts was performed to analyze expression of multiple genes involved in fibrosis.
Results: Both groups survived long-term (>100 days). The allogeneic grafts were infiltrated by significantly
increased numbers of CD4+ (P <0.0001), CD8+ (P <0.0001), and CD11b+ cells (P = 0.0065) by day 100. Furthermore,
elevated IL-13 levels (P = 0.0003) and numbers of infiltrating IL-13+ cells (P = 0.0037), together with an expression of
IL-13Rα2, were detected only within allografts. The expression of IL-13 and IL-13Rα2 resulted in significantly
increased TGF-β1 levels (P <0.0001), higher numbers of CD11bhighGr1intermediateTGF-β1+ cells, and elevated cardiac
collagen deposition (P = 0.0094). The allograft fibrosis found in these experiments was accompanied by
upregulation of multiple profibrotic genes, which was confirmed by immunohistochemical stainings of allograft
tissue. Blockage of the IL-13/TGF-β1 interaction by IL-13Rα2 siRNA led to lower numbers of
CD11bhighGr1intermediateTGF-β1+, CD4+, CD8+, and CD11b+ cells, and prevented collagen deposition (P = 0.0018)
within these allografts.
Conclusions: IL-13 signaling via IL-13Rα2 induces TGF-β1 and causes allograft fibrosis in a murine model of chronic
transplant rejection. Blockage of this IL-13/TGF-β1 interaction by IL-13Rα2 siRNA prevents cardiac allograft fibrosis.
Thus, IL-13Rα2 may be exploitable as a future target to reduce allograft fibrosis in organ transplantation.
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Heart transplantation is an effective therapy for chronic
heart failure [1]. Recent immunosuppressive strategies
have reduced acute rejection episodes and improved early
cardiac graft survival [2]. However, these improvements
did not ameliorate chronic allograft rejection, which re-
mains an obstacle for better long-term heart transplant
survival [3]. Chronic rejection of an allograft causes an in-
timal fibrosis in the vessels that leads to cardiac allograft
vasculopathy [4]. Another consequence of chronic rejec-
tion and inflammation is cardiac fibrosis accompanied by
increased stiffness of the heart and diminished contractil-
ity [5]. Ultimately, these fibrotic reactions can result in
myocardial infarction or sudden death [4,6].
On a molecular level, fibrosis is associated with a disrup-
tion of the extracellular matrix and with deposition of
extracellular collagen produced by myofibroblasts [5]. In
various studies TGF-β1 has been identified as the key cyto-
kine orchestrating fibrosis development [7,8]. TGF-β1 is
produced by macrophages after stimulation by IL-13 via
the IL-13Rα2 in the presence of IL-4 or TNF-α [9]. Further
studies have shown that this pathway is a key initiation
point for a complex fibrotic program in chronic TNBS
colitis [10]. Additionally, it has been demonstrated that
TGF-β1 inhibition ameliorates lung fibrosis, chronic allo-
graft nephropathy, and also cardiac allograft fibrosis
[11-13]. However, no effective therapy to prevent heart
allograft fibrosis has been identified so far, possibly be-
cause ideal murine transplant models have been lacking to
study potential targets and therapies. A mouse model for
the examination of cardiac allograft fibrosis should enable
long-term survival of a transplanted allograft and develop
cardiac fibrosis in the setting of chronic rejection. Tanaka
et al. have developed a transplantation model in which
FVB (H-2q) donor hearts were placed into DBA/1 recipi-
ents that display a similar major histocompatibility com-
plex (MHC) (H-2q), but different non-MHC genes (CD5,
CD8a, NK1.1, and Thy-1) [14]. In this model, the heart al-
lografts survive for up to more than 100 days without im-
munosuppression and developed graft coronary artery
disease as the result of chronic rejection.
The present study was performed under the hypoth-
esis that the FVB to DBA/1 model is appropriate to
examine cardiac graft fibrosis. Further, we hypothesized
that TGF-β1 stimulated by IL-13 signaling through IL-
13Rα2 is responsible for this allograft fibrosis and that
blockage of the pathway by IL-13Rα2-specific siRNA can
ameliorate allograft fibrosis.
Materials and methods
Mice and heterotopic heart transplantation
Female DBA/1 (H-2q), FVB (H-2q), and as controls
BALB/c and C57BL/6 mice, 10 to 12 weeks old, were
purchased from The Jackson Laboratory (Bar Harbor,ME, USA) and housed at our local animal care facility.
Animal use adhered to institutional guidelines.
Vascularized cardiac allografts were transplanted into
the abdomen using a microsurgical technique as previ-
ously described by Corry et al. [15]. Donor hearts were
perfused via the abdominal vena cava and additionally
via the aortic arch with cold 0.9% saline (3 mL each)
containing 500 IE heparin. Graft function was assessed
by palpation of the abdomen and rejection was defined
as cessation of cardiac contractility. All donor hearts
had palpable contractions at the time of recovery (60 or
100 days; acute rejection 8 days).
IL-13Rα2-specific siRNA
IL-13Rα2-specific siRNA and control (scrambled) siRNA
for use in gene silencing studies were obtained from
Dharmacon (Chicago, IL, USA). The siRNA (100 μg)
was encapsulated in HVJ-E and prepared as previously
described before administration by intraperitoneal injec-
tion (100 μL) every other day [10,16]. The sequence used
for the siRNA is 5′-GGAATCTAATTTACAAGGA-3′.
Histology and immunohistochemistry
Formalin-fixed and paraffin-embedded samples were pre-
pared and sectioned (2 to 3 μm). Tissue sections were
stained with Masson’s trichrome. Frozen sections (2 to
3 μm) were blocked with 1% BSA (Biomol, Hamburg,
Germany), 10% goat serum (Sigma-Aldrich, St Louis, MO,
USA), or an antibody dilution buffer. As primary anti-
bodies, rat monoclonal anti-mouse CD11b (557395; BD,
Heidelberg, Germany), CD4 (550280; BD), and CD8
antibodies (Ab25478; Abcam, Cambridge, UK), a goat
polyclonal anti-mouse IL-13 antibody (AF-413-NA;
R&D Systems, Minneapolis, MN, USA) and a rabbit
polyclonal anti-mouse Fas ligand (Ab15285; Abcam), a
rabbit polyclonal anti-mouse matrix metalloproteinase
(MMP)-1 (orb101432; Biorbyt, Cambridge, UK), a rabbit
polyclonal anti-mouse MMP-13 (Ab39012; Abcam), a
rabbit polyclonal anti-mouse β2-microglobulin (Ab87483;
Abcam), and a rabbit polyclonal anti-mouse Gremlin-1
antibody (Ab90670; Abcam) were used. After staining with
goat anti-rat-Fab2 (sc-3822; Santa Cruz Biotechnology,
Heidelberg, Germany), donkey anti-goat-Fab2 (sc-2042;
Santa Cruz), or goat anti-rabbit-Fab2 (Ab64256; Abcam)
secondary antibody, sections were incubated with SensiTek
HRP (ScyTec Laboratories, Logan, UT, USA) and positive
signals were visualized using a 3,3′-diaminobenzidine-
tetrahydrochlorhydrate (DAB) kit (Merck, Darmstadt,
Germany) or AEC+ High Sensitivity Substrate Chromogen
kit (Dako, Hamburg, Germany). Images were captured using
an Axio Observer Z1 microscope (Carl Zeiss, Oberkochen,
Germany). For quantifying graft-infiltrating leukocytes,
three high power fields (HPFs; 20x magnification) were
counted per slide by two independent examiners.
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Cells were lysed with radioimmunoprecipitation assay buf-
fer and the whole cell lysates obtained were subjected to
SDS-PAGE. The separated proteins obtained were trans-
ferred to a nitrocellulose membrane and immunoblotted.
IL-13Rα2 was detected by incubation with a monoclonal
rat anti-mouse IL-13Rα2 (R&D Systems), followed by in-
cubation with horseradish peroxidase-conjugated anti-rat
IgG (Invitrogen, Carlsbad, CA, USA). Membranes were
developed with SuperSignal West Pico Chemiluminescent
Substrate (Pierce Chemical, Dallas, TX, USA) and exposed
to X-ray film.
Collagen assay
Heart allografts were harvested on day 60 and day 100
after transplantation, and homogenized in 0.5 mol/L
acetic acid containing pepsin (at a concentration of 10
mg tissue/10 mL of acetic acid solution). The resulting
mixture was then incubated and stirred for 24 hours at
4°C. Total soluble collagen content of the mixture was
then determined with a Sircol Collagen Assay kit
(Biocolor, Carrickfergus, UK), as described by the manu-
facturer. Acid soluble type I collagen supplied with the
kit was used to generate a standard curve.
Cell isolation from cardiac grafts and spleens
Cardiac tissue was minced in 10 mL of RPMI 1640
medium with 10% FCS, 600 U/mL collagenase II (Roche
Diagnostics, Mannheim, Germany), and deoxyribonucle-
ase I (DNase; Sigma-Aldrich). This mixture was shaken
at room temperature for 2 hours and supernatant was
flushed through a 100 μm nylon cell strainer (Schubert
& Weiss, Munich, Germany). Remaining tissue was
again digested in 5 mL of RPMI-collagenase-DNase so-
lution at 37°C and strained through a 100 μm nylon
strainer. Splenic tissue was minced and strained through
a 100 μm nylon strainer. Digested cell suspensions were
centrifuged for 5 minutes at 1,500 rpm (4°C). To remove
red blood cells, the pellet was treated with ACK lysis
buffer (Lonza Walkersville, Walkersville, MD, USA) and
incubated for 2 minutes at room temperature. After cen-
trifugation, cells were suspended in HBSS medium
(Gibco, Grand Island, NY, USA) and counted.
Flow cytometry
Cell isolates were blocked with 1% mouse serum (Dako,
Glostrup, Denmark) and stained with appropriate non-
overlapping conjugated monoclonal antibodies (anti-
Gr1 antibody from Miltenyi Biotec, Bergisch Gladbach,
Germany; all other antibodies from eBioscience, San
Diego, CA, USA). Intracellular staining was carried out
by first fixing and permeabilizing cells with Cytofix/
Cytoperm solution (BD Pharmingen, San Diego, CA,
USA). Analyses were performed using a FACSCanto IIflow cytometer (BD Biosciences, San Jose, CA, USA).
Data were obtained using BD CellQuest Pro acquisition
software (BD Biosciences) and analyzed via FlowJo soft-
ware (Tree Star Inc, Ashland, OR, USA).
ELISA
Heart allografts were harvested at day 60 and day 100,
and graft-infiltrating cells were isolated. Isolated graft-
infiltrating cells were cultured at 37°C. For IL-13, we cul-
tured 1 × 106 cells per 1 mL medium for 48 hours;
for TGF-β1 measurements, we cultured 1 × 10
5 cells per
100 μL medium for 24 hours. During the culture period
cells were stimulated with plate-bound anti-CD3 antibody
(10 μg/mL) and soluble anti-CD28 antibody (1 μg/mL; BD
Biosciences Pharmingen) for measurement of IL-13 (R&D
Systems). For determination of TGF-β1 levels (Invitrogen)
cells were stimulated with plate-bound anti-CD3 antibody
(10 μg/mL), soluble anti-CD28 antibody (1 μg/mL), and
recombinant murine IL-13 (20 ng/mL; R&D Systems).
Cytokine concentrations were determined in duplicate by
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s instructions. TGF-β1 was measured
in medium containing TGF-β1-depleted human serum.
RNA isolation and PCR array
In heart allografts recovered on day 100 after transplant-
ation, RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany), as described by the manu-
facturer. One microgram of total RNA was reverse tran-
scribed using the AffinityScript QPCR cDNA Synthesis
Kit (Agilent Technologies, Böblingen, Germany). Expres-
sion of genes relevant for fibrosis was determined with a
Mouse Fibrosis RT2 Profiler PCR Array (SA Biosciences,
Hilden, Germany) using the LightCycler 480 Real-Time
PCR System (Roche).
Statistics
All data, unless otherwise specified, are shown as the
mean ± standard error of the mean (SEM), and were
compared using a two-tailed Student’s test. The level of
significance was set at a probability of P <0.05.
Results
FVB allografts transplanted in DBA/1 recipients showed
significantly increased infiltration by CD4+, CD8+, and
CD11b+ cells
To determine the number of graft-infiltrating cells, heart
allografts were harvested on day 60 and day 100 after trans-
plantation, and were stained for CD4, CD8, and CD11b. In
syngeneic grafts (DBA/1 into DBA/1), low numbers of
CD4+ (day 60, 16 ± 3 and day 100, 9 ± 1 cells/HPF), CD8+
(day 60, 15 ± 2 and day 100, 12 ± 3 cells/HPF), and
CD11b+ cells (day 60, 6 ± 1 and day 100, 22 ± 5 cells/HPF)
were detected (Figure 1A,B,C,D,E,F). Allogeneic heart grafts
Figure 1 Increased infiltration by CD4+, CD8+, and CD11b+ cells in allogeneically transplanted grafts. (A,B,C) Representative stainings for
CD4, CD8, and CD11b in syngeneic (DBA/1 into DBA/1) or allogeneic (FVB into DBA/1) heart allografts explanted at day 100 after transplantation.
(D) In FVB into DBA/1 transplanted hearts, significantly elevated numbers of CD4+ cells were detected (day 60, P = 0.0007 and day 100,
P <0.0001; day 60 versus day 100, P = 0.0009) in comparison to DBA/1 into DBA/1 transplanted grafts. (E) FVB allografts transplanted into DBA/1
recipients showed numbers of CD8+ cells (day 60, P <0.0001 and day 100, P <0.0001; day 60 versus day 100, P = 0.1921) that were significantly
higher than in the syngeneic group. (F) Significantly higher levels of CD11b+ cells were found in allogeneic (FVB into DBA/1) grafts (day 60,
P = 0.0045 and day 100, P = 0.0065; day 60 versus day 100, P = 0.0124) when compared to DBA/1 to DBA/1 transplanted hearts. The histological
score is the mean of 3 HPF (20× magnification); at least five mice per group were analyzed. *P <0.05. HPF, high power field.
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significantly higher cell numbers of CD4+ (63 ± 11 cells/
HPF; P = 0.0007), CD8+ (121 ± 11 cells/HPF; P <0.0001),
and CD11b+ cells (31 ± 7 cells/HPF; P = 0.0045) compared
to grafts in the syngeneic group. The numbers of CD4+ and
CD11b+ cells in the FVB into DBA/1 group increased
further by day 100 after transplantation (day 60 versus day
100, CD4+ P = 0.0009; CD11b+ P = 0.0124), whereas the
increase in the number of CD8+ cells did not reach statis-
tical significance (P = 0.1921). In comparison to control
animals at day 100 after transplantation, the allogeneic group
showed significantly higher levels of CD4+ (199 ± 31 cells/
HPF; P < 0.0001), CD8+ (149 ± 17 cells/HPF; P <0.0001),
and CD11b+ cells (128 ± 34 cells/HPF; P = 0.0065).FVB allografts transplanted into DBA/1 recipients showed
significantly increased levels of IL-13, IL-13Rα2, and TGF-β1
To examine if TGF-β1 stimulated by IL-13 signaling is
elevated in mice receiving allogeneic transplants, IL-13
levels were measured by ELISA in supernatants of
cultured allograft-infiltrating cells. Syngeneic DBA/1 heart
grafts showed similar IL-13 concentrations at day 60
(108 ± 13 pg/mL) and at day 100 (112 ± 12 pg/mL)
(P = 0.8415). FVB allografts placed in DBA/1 recipients
showed significantly elevated IL-13 levels at day 60 (187 ±
10 pg/mL; P = 0.0031) and at day 100 after transplantation
(303 ± 23 pg/mL; P = 0.0003) in comparison to allogeneic
grafts at the same respective time points (Figure 2A).
Additionally, immunohistochemical staining for IL-13 in
Figure 2 Activation of IL-13/TGF-β1 pathway in allogeneically transplanted grafts. (A) ELISA of supernants of cultured allograft-infiltrating
cells detected significantly elevated IL-13 levels in allografts (day 60, P = 0.0031 and day 100, P = 0.0003)compared to syngrafts or FVB control
hearts (P = 0.0055 and P = 0.0042). (B) Immunohistochemistry showed significantly higher and over time increasing numbers of IL-13+ cells in
FVB hearts transplanted into DBA/1 recipients (day 60, P = 0.0228; day 100, P = 0.0037) relative to syngeneic animals (day 60 versus day 100,
P = 0.0083). (C) Representative immunohistochemical stainings showed more IL-13+ cells in allografts ( FVB into DBA/1) compared to controls
(DBA/1 into DBA/1; day 100). (D) Western blot analysis revealed expression of IL-13Rα2 only in allograft-infiltrating cells isolated from
allogeneically transplanted hearts (FVB into DBA/1) in contrast to cells isolated from FVB controls or syngrafts (DBA/1 into DBA/1) without IL-13Rα
2 expression. (E) Measurement of TGF-β1 by ELISA detected significantly elevated TGF-β1 levels in cells isolated from DBA/1 mice grafted with FVB
hearts at day 60 (88 ± 5 versus 46 ± 5 pg/mL; P = 0.0010) and at day 100 (133 ± 6 versus 42 ± 7 pg/mL; P <0.0001) in comparison to syngrafts,
and FVB control hearts (40 ± 8 pg/mL; P = 0.0048 and P = 0.0009, respectively). (F) Flow cytometry of graft-infiltrating cells extracted from
allografts showed a higher percentage of CD11bhighGr1intermediateTGF-β1
+ cells (7.3%) than in the syngeneic controls (1.2%; day 100). (G) In the
flow cytometric analysis (pre-gated for CD45) these CD11bhigh cells were the only source of TGF-β1 production. The histological score is the mean
of 3 HPF (20x magnification); at least five mice per group were analyzed. *P <0.05. ELISA, enzyme-linked immunosorbent assay; HPF, high power
field; IL-13, interleukin 13; TGF-β1, transforming growth factor beta 1.
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nificantly increased numbers of IL-13+ cells/HPF at day 60
(16 ± 4 versus 6 ± 2 cells/HPF; P = 0.0228) and at day 100
(96 ± 26 versus 7 ± 2 cells/HPF; P = 0.0037), relative to the
syngeneic controls (day 60 versus day 100; P = 0.0083;
Figure 2B,C). Western blot analyses of lysates from allograft-
infiltrating cells indicated detectable expression of IL-13Rα2
only in the allogeneic FVB to DBA/1 mice, both at day 60
and at day 100 after heart transplantation (Figure 2D).As the next step, the effector cytokine TGF-β1 was mea-
sured by ELISA after culturing and stimulating cells iso-
lated from the allografts. In DBA/1 mice grafted with FVB
hearts, significantly elevated TGF-β1 levels were detected
at day 60 (88 ± 5 versus 46 ± 5 pg/mL; P = 0.0010) and at
day 100 (133 ± 6 versus 42 ± 7 pg/mL; P < 0.0001) in com-
parison to the syngeneic controls, and also versus the FVB
control heart transplants (40 ± 8 pg/mL; P = 0.0048 and
P = 0.0009, respectively; Figure 2E). In accordance with
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extracted from allogeneic grafts at day 100 showed a
higher percentage of CD11bhighGr1intermediateTGF-β1
+ cells
(7.3%) than in the syngeneic controls (1.2%; Figure 2F).
Furthermore, flow cytometry demonstrated that these
CD11bhigh cells were likely the only source of TGF-β1 pro-
duction in this transplantation model (Figure 2G).FVB allografts transplanted into DBA/1 recipients showed
significantly increased levels of collagen deposition
To prove that FVB hearts transplanted in DBA/1 mice
develop fibrosis, Masson’s trichrome staining was
performed. In these stainings, a strong collagen de-
position was found in the allogeneic grafts at day 60,
with a further increase in collagen deposition by day
100 after heart transplantation. No such fibroticFigure 3 Increased collagen deposition in allogeneically transplanted
increased levels of collagen (blue color) in allogeneically (FVB into DBA/1) c
explanted at day 60 and day 100 after transplantation (5× and 20× magnif
amounts of collagen in FVB hearts placed into DBA/1 recipients at day 60 (
to the DBA/1 to DBA/1 mice and also to FVB control hearts (P = 0.0094). Acollagen deposition was observed in the syngeneic con-
trol mice (Figure 3A).
A Sircol assay was conducted to better quantify collagen
levels in heart allografts. With this method, the amount of
collagen was found to be significantly greater in FVB hearts
placed into DBA/1 recipients at day 60 (105 ± 13 versus
61 ± 9 μg/mg allograft protein; P = 0.0342) and at day
100 after transplantation (139 ± 11 versus 54 ± 12 μg/mg
allograft protein; P = 0.0022) compared to the DBA/
1-to-DBA/1 mice and also to FVB control hearts
(P = 0.0094; Figure 3B).
FVB allografts transplanted into DBA/1 recipients showed
upregulation of profibrotic and downregulation of
antifibrotic genes
To demonstrate at an mRNA-level that allogeneic grafts
have upregulated profibrotic genes, RNA was isolatedgrafts. (A) Representative Masson’s trichrome stainings showed
ompared to syngeneically (DBA/1 into DBA/1) transplanted hearts
ication). (B) Analysis by Sircol assay detected significantly higher
P = 0.0342) and at day 100 after transplantation (P = 0.0022) compared
t least five mice per group were analyzed. *P < 0.05.
Figure 4 Activation of a ‘fibrotic program’ in allogeneically transplanted grafts. (A,B) PCR array using RNA extracted from explanted hearts
(day 100) of allogeneically (FVB into DBA/1) or syngeneically (DBA/1 into DBA/1) transplanted mice demonstrated an upregulation of pro-fibrotic
genes and a downregulation of anti-fibrotic genes in the allogeneic group.
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This PCR array, which profiles the expression of 84 key
genes involved in tissue remodeling and fibrosis, revealed
an upregulation of IL-13 and TGF-β1 (as detected in the
previous experiments), but also a strong upregulation of
other cytokines relevant for fibrosis, including IL-1α,
IL-1β, and TNF-α. Further, chemokines such as Ccl3,
Ccl12, Ccr2, and Cxcr4, and genes involved in epithelial-
mesenchymal transition or cell adhesion such as Fas ligand,
β2-microglobulin, integrin-α2, integrin-β6, MMP-1a, and
MMP-13, were upregulated; in contrast, Gremlin-1 and
Smad6 were downregulated (Figure 4A,B).
Additionally, immunohistochemical labeling was per-
formed for selected targets. According to these PCR
array results, FVB allografts placed into DBA/1 recipi-
ents showed strong positivity for Fas ligand, MMP-1,
MMP-13, and β2-microglobulin at day 100, whereas
Gremlin-1 staining was stronger in the syngeneic group
(Figure 5). In comparison to acutely rejected grafts
(BALB/c to C57BL/6), and also to naive non-transplanted
FVB hearts, this expression pattern was unique in fibrosis
of FVB allografts transplanted into DBA/1 recipients.
Specific blockage of IL-13Rα2 abrogates TGF-β1
production and prevents allograft fibrosis
To investigate if allograft fibrosis depends on TGF-β1
production stimulated by IL-13 secretion, IL-13 signal-
ing in DBA/1 recipients grafted with FVB hearts was
inhibited by intraperitoneal treatment with specific IL-13Rα2 siRNA or control siRNA. Flow cytometric analysis
of graft-infiltrating cells from hearts harvested 100 days
after transplantation showed a low percentage of
CD11bhighGr1intermediateTGF-β1
+ cells (0.3%) in the siRNA-
treated group compared to controls (4.2%; Figure 6A).
Furthermore, quantification of collagen by the Sircol assay
showed significantly less collagen levels in mice treated
with specific IL-13Rα2 siRNA compared to mice treated
with control siRNA (122 ± 23 versus 314 ± 28 μg/mg
allograft protein; P = 0.0018) (Figure 6B). This was in
accordance with Masson’s trichrome staining, in which
only small areas of collagen deposition were observed in
siRNA-treated hearts, whereas extensive amounts of
collagen were detected in control allografts (Figure 6C).
To test whether the differences in TGF-β1 production
caused imbalances in CD4+Foxp3+ regulatory T cells
(Tregs), a flow cytometric analysis of cells from allografts
was performed 100 days after transplantation. However,
CD4+Foxp3+ Tregs were found to be present at equal
levels in siRNA- and control siRNA-injected animals
(15.6% versus 15.2%, respectively; Figure 6D). Immunohis-
tochemical staining of allografts after therapy with specific
IL-13Rα2 siRNA showed levels of CD4
+, CD8+, and
CD11b+ cells that were much lower after treatment with
control siRNA, but similar to syngeneic transplanted ani-
mals (Figure 6E versus Figure 1A,B,C).
In this study we demonstrate for the first time that
allograft fibrosis is caused by IL-13 signaling through the
receptor IL-13Rα2, which consequently leads to elevated
Figure 5 Immunohistochemical analysis of the ‘fibrotic program’ active in allogeneically transplanted grafts. Representative
immunohistochemical stainings show strong positivity for Fas ligand, MMP-1, MMP-13, and β2-microglobulin in allogeneically (FVB into DBA/1)
and for Gremlin-1 in syngeneically (DBA/1 into DBA/1) transplanted hearts explanted at day 100, in comparison to naive non-transplanted FVB
hearts and acutely rejected (BALB/c into C57BL/6) allografts (20× magnification). MMP, matrix metalloproteinase.
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in heart allografts. Additionally, we show that inhibition
of this pathway by siRNA specific for IL-13Rα2 prevents
allograft fibrosis.
The findings presented here that link IL-13 signaling via
IL-13Rα2 to allograft fibrosis are based on our previous
studies showing that such signaling is essential in the devel-
opment of inflammation-associated fibrosis [9,10,17]. These
studies showed that IL-13 induces TGF-β1 via a two-stage
process involving: 1) induction of IL-13Rα2 expression by
IL-13 (or IL-4) signaling via IL-13Rα1, combined with
TNF-α signaling through its receptor; and 2) IL-13 signal-
ing via IL-13Rα2 to induce an AP-1 variant containing
c-Jun and Fra-2 that activates the TGF-β1 promoter [9].
The importance of this pathway for development of fibrosis
has been shown extensively by our group in bleomycin-
induced lung fibrosis and chronic TNBS-induced colitis
[10,17]. Thus, these previous studies provided the basis to
investigate the importance of IL-13/TGF-β1 signaling in
the setting of allograft fibrosis.The study presented here shows increasing levels of IL-
13 and IL-13+ cells within allografts of transplanted mice,
in contrast to control mice receiving syngeneic grafts.
Multiple studies have demonstrated that IL-13 is essential
for the development of dermal, gastrointestinal, and pul-
monary fibrosis, as well as fibro-obliterative lesions found
in the bronchiolitis obliterans (BO) syndrome [9,10,17-20].
Consistent with these studies, IL-13Rα2 was detected only
in the FVB allografts transplanted into DBA/1 recipients
in our experiments. This receptor has been shown to link
IL-13 signaling with further fibrotic downstream effects
[9,21]. In follow-up, we detected elevated levels of TGF-β1
in the mice receiving allogeneic grafts exclusively. Results
from previous studies have indicated that TGF-β1 is the
key cytokine for development of allograft fibrosis in mur-
ine models and in humans, and that depletion of TGF-β1
can prevent allograft fibrosis [7,12,22]. Other cytokines
such as IL-6 and IL-17 can modulate the TGF-β1-medi-
ated fibrotic reactions [7,8]. Additionally, a study by Faust
et al. concluded that T cell TGF-β signaling was required
Figure 6 Blockage of IL-13Rα2 prevents TGF-β1 production and fibrosis in allogeneically transplanted grafts. (A) Flow cytometric analysis
of graft-infiltrating cells of allogeneically (FVB into DBA/1) transplanted hearts (day 100) detected a strongly diminished percentage of
CD11bhighGr1intermediateTGF-β1
+ cells (0.3%) in the siRNA-treated group compared to the control animals (4.2%). (B) Quantification of collagen by
Sircol assay showed significantly less collagen levels in mice injected with specific IL-13Rα2 siRNA (P = 0.0018) than mice treated with control
siRNA. Levels were not significantly different to FVB control hearts (P = 0.1309). (C) Representative Masson’s trichrome stainings showed reduced
levels of collagen in allogeneically (FVB into DBA/1) transplanted hearts treated with siRNA compared to mice treated with control peptide (day
100 after transplantation; 20x magnification). (D) In flow cytometric analysis the frequency of CD4+Foxp3+ Tregs isolated from allogeneically
transplanted grafts (day 100) was similar in siRNA- and control siRNA-injected animals (15.6 versus 15.2%). (E) Representative
immunohistochemical stainings (day 100) showed numbers of CD4+, CD8+, and CD11b+ cells in FVB allografts transplanted into DBA/1 mice and
treated with siRNA that were lower than mice treated with control siRNA and comparable to syngeneic control grafts (Figure 1 A,B,C). At least
five mice per group were analyzed. *P <0.05. Treg, regulatory T cell.
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the elevated levels of TGF-β1, we found increased
allograft-infiltration with CD11bhighGr1intermediateTGF-β1
+
cells in the DBA/1 mice transplanted with FVB allografts;
it has been shown by our group and others that
CD11bhighGr1intermediate cells are the main source for
TGF-β1 production [23-25]. In the allogeneic situation of
the mouse model we used, activation of the profibrotic IL-
13/TGF-β1 interaction led to allograft fibrosis that was
continuously increasing over time after transplantation.
Another important finding from this study is that allograft
fibrosis can be prevented by blockage of the IL-13/TGF-β1
interaction through specific IL-13Rα2 siRNA. Aftertreatment with IL-13Rα2 siRNA, an almost complete re-
duction of TGF-β1 production by CD11b
highGr1intermediate
cells (the main producers of TGF-β1 in this model) was
observed [24,25]. The reduction of TGF-β1-producing
cells and reduced TGF-β1 levels consequently led to di-
minished collagen deposition in heart allografts and there-
fore reduced allograft fibrosis. Tregs were also considered
as contributors to the TGF-β1 effect. While CD4
+Foxp3+
Tregs can produce TGF-β1 to mediate their tolerogenic
functions and expand induced regulatory T cells (iTregs),
there was no difference in their numbers in control versus
IL-13Rα2 siRNA-injected mice [26-29]. Notably, after
therapy with IL-13Rα2 siRNA, CD4
+ and CD8+ cells were
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eic grafts, and were much lower than in allotransplanted
mice not given IL-13Rα2 siRNA treatment.
For our investigations, we used a heterotopic murine
heart transplantation model in which FVB hearts were
placed in DBA/1 recipients. This chronic rejection model
with minor multiple non-MHC mismatches has been used
previously to study graft coronary artery disease [14]. We
show that the FVB to DBA/1 model can also be used to
examine allograft fibrosis. Over time, transplanted allografts
are infiltrated by increasing numbers of CD4+, CD8+, and
CD11b+ cells, a fact that was also observed by Tanaka
et al. in the original description of this transplantation
model [14]. We further demonstrated by PCR array that a
‘fibrotic program’ is active in this FVB to DBA/1 model.
Profibrotic factors such as IL-1α and IL-1β that play a role
in liver fibrosis development, and TNF-α which is an es-
sential cofactor of IL-13 to induce the expression of IL-
13Rα2, were upregulated. Further, Ccl-12 and Cxcr-4 that
were both shown to be involved in pulmonary fibrosis,
Ccl-3 which has been described to be important in
systemic sclerosis, and Ccr-2 that is associated with
allograft fibrosis, were overexpressed [9,30-33]. Add-
itionally, the PCR array showed upregulation of other
influential molecules such as Fas/Fas ligand, which is
important in the development of fibrotic lesions associ-
ated with adult respiratory distress syndrome (ARDS).
MMP-1 and MMP-13 (involved in remodeling pro-
cesses occurring during fibrosis) and β2-microglobuin
were also overexpressed in the PCR array and positive in
the immunohistochemistry of FVB allografts transplanted
into DBA/1 recipients [34-36]. In contrast, genes like
Gremlin-1 that may contribute to reversibility of lung fi-
brosis in rats, and Smad6 which in complex with Smurf-1
effectively attenuated TGF-β1 signaling, were down-
regulated [37,38]. Altogether, these findings support the
fact that this FVB to DBA/1 transplantation model is suit-
able not only to study graft coronary artery disease, but
also to examine organ allograft fibrosis.
Conclusions
In conclusion, this study shows that IL-13 signaling via IL-
13Rα2 induces TGF-β1 and causes allograft fibrosis in a
chronic transplant rejection model that is now also est-
ablished as a model to study allograft fibrosis. Further, we
demonstrate in this study that blockage of this IL-13/TGF-
β1 interaction by IL-13Rα2 siRNA prevents heart allograft fi-
brosis. Together, our results indicate that IL-13Rα2 may be
exploitable as a future target to reduce allograft fibrosis in
organ transplantation.
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